8-K 1 doc1.txt SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities and Exchange Act of 1934 Date of Report (Date of earliest event reported) June 27, 2003 ------------------ CALYPTE BIOMEDICAL CORPORATION. -------------------------------- Exact name of Registrant as specified in its Charter) DELAWARE -------- (State or other jurisdiction of incorporation) 000-20985 06-1226727 --------- ---------- Commission File No. I.R.S. Employer Identification 1265 Harbor Bay Parkway, Alameda, CA 94502 ----------- ----- Address of principal executive offices Zip Code (510) 749-5100 -------------- Registrant's telephone number, including area code ITEM 5. OTHER EVENTS AND REGULATION FD DISCLOSURE On June 27, 2003 the Registrant (the "Company") entered into a Separation Agreement, mutual release and waiver of claims with Nancy E. Katz, the Company`s former Chief Executive Officer effective June 2, 2003. Ms. Katz also currently resigned as a director of the Company, and did not have any disagreement with the Company`s operations, policies or practices. ITEM 7. FINANCIAL STATEMENTS AND EXHIBITS 99.1 Calypte Biomedical Press Release dated June 27, 2003. SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Dated: Alameda, California June 27, 2003 CALYPTE BIOMEDICAL CORPORATION (Registrant) /s/ Richard D. Brounstein ---------------------------------- Richard D. Brounstein Executive Vice President and Chief Financial Officer